Barbara A Konkle

List of Publications by Year
in descending order

226	13,270	53794 45	25787 108
papers	citations	h-index	g-index

239	239	239	14579
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Genetic determinants of telomere length from 109,122 ancestrally diverse whole-genome sequences in TOPMed. Cell Genomics, 2022, 2, 100084.	6.5	29
2	Phenotypic analysis of erythrocytes in sickle cell disease using imaging flow cytometry. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2022, 101, 448-457.	1.5	3
3	Laboratory assays of VWF activity and use of desmopressin trials in the diagnosis of VWD: a systematic review and meta-analysis. Blood Advances, 2022, 6, 3735-3745.	5.2	3
4	Assessing the contribution of rare variants to complex trait heritability from whole-genome sequence data. Nature Genetics, 2022, 54, 263-273.	21.4	156
5	Mendelian randomization supports bidirectional causality between telomere length and clonal hematopoiesis of indeterminate potential. Science Advances, 2022, 8, eabl6579.	10.3	36
6	Influence of N-glycosylation in the A and C domains on the immunogenicity of factor VIII. Blood Advances, 2022, 6, 4271-4282.	5.2	5
7	Comorbidities, Health-Related Quality of Life, Health-care Utilization in Older Persons with Hemophiliaâ€"Hematology Utilization Group Study Part VII (HUGS VII). Journal of Blood Medicine, 2022, Volume 13, 229-241.	1.7	2
8	Results of genetic analysis of 11â€‰341 participants enrolled in the My Life, Our Future hemophilia genotyping initiative in the United States. Journal of Thrombosis and Haemostasis, 2022, 20, 2022-2034.	3.8	10
9	The critical need for postmarketing surveillance in gene therapy for haemophilia. Haemophilia, 2021, 27, 126-131.	2.1	11
10	BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression. Blood, 2021, 137, 763-774.	1.4	94
11	Diagnosis and management of von Willebrand disease: A communityâ€wide effort to deliver evidenceâ€based clinical practice guidelines. Haemophilia, 2021, 27, 181-183.	2.1	1
12	Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. Nature, 2021, 590, 290-299.	27.8	1,069
13	Patientâ€relevant health outcomes for hemophilia care: Development of an international standard outcomes set. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12488.	2.3	20
14	Chromosome Xq23 is associated with lower atherogenic lipid concentrations and favorable cardiometabolic indices. Nature Communications, 2021, 12, 2182.	12.8	17
15	Genome sequencing unveils a regulatory landscape of platelet reactivity. Nature Communications, 2021, 12, 3626.	12.8	29
16	Site-Specific N- and O-Glycosylation Analysis of Human Plasma Fibronectin. Frontiers in Chemistry, 2021, 9, 691217.	3.6	8
17	Whole-genome association analyses of sleep-disordered breathing phenotypes in the NHLBI TOPMed program. Genome Medicine, 2021, 13, 136.	8.2	16
18	How do Iâ€¦ facilitate a rapid response to a public health emergency requiring plasma collection with a publicâ€“private partnership?. Transfusion, 2021, 61, 2814-2824.	1.6	2

#	Article	IF	Citations
19	ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Advances, 2021, 5, 280-300.	5.2	246
20	A Prospective Observational Study of Antihemophilic Factor (Recombinant) Prophylaxis Related to Physical Activity Levels in Patients with Hemophilia A in the United States (SPACE). Journal of Blood Medicine, 2021, Volume 12, 883-896.	1.7	3
21	A high-resolution HLA reference panel capturing global population diversity enables multi-ancestry fine-mapping in HIV host response. Nature Genetics, 2021, 53, 1504-1516.	21.4	69
22	Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors. The Cochrane Library, 2020, 2020, CD011441.	2.8	10
23	An international survey to inform priorities for new guidelines on von Willebrand disease. Haemophilia, 2020, 26, 106-116.	2.1	32
24	Urinary cross-linked carboxyterminal telopeptide, a bone resorption marker, decreases after vaso-occlusive crises in adults with sickle cell disease. Blood Cells, Molecules, and Diseases, 2020, 80, 102369.	1.4	2
25	Making Knowledge Hereditary: Publicâ€"Private Partnership Drives Progress in Rare Disease Community. Social Marketing Quarterly, 2020, 26, 218-228.	1.7	2
26	Inherited causes of clonal haematopoiesis in 97,691 whole genomes. Nature, 2020, 586, 763-768.	27.8	376
27	Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2020, 18, 3074-3077.	3.8	24
28	BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A. New England Journal of Medicine, 2020, 383, 1018-1027.	27.0	76
29	Dynamic incorporation of multiple in silico functional annotations empowers rare variant association analysis of large whole-genome sequencing studies at scale. Nature Genetics, 2020, 52, 969-983.	21.4	146
30	Loss-of-function genomic variants highlight potential therapeutic targets for cardiovascular disease. Nature Communications, 2020, 11, 6417.	12.8	39
31	Minimal Essential Human Factor VIII Alterations Enhance Secretion and Gene Therapy Efficiency. Molecular Therapy - Methods and Clinical Development, 2020, 19, 486-495.	4.1	11
32	World Federation of Hemophilia Gene Therapy Registry. Haemophilia, 2020, 26, 563-564.	2.1	28
33	Modeling to Predict Factor VIII Levels Associated with Zero Bleeds in Patients with Severe Hemophilia A Initiated on Tertiary Prophylaxis. Thrombosis and Haemostasis, 2020, 120, 728-736.	3.4	19
34	Use of convalescent plasma in hospitalized patients with COVID-19: case series. Blood, 2020, 136, 759-762.	1.4	124
35	Longâ€term safety and efficacy results from the phase 3b, openâ€label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A. Haemophilia, 2020, 26, e168-e178.	2.1	20
36	Identification of Key Coagulation Activity Determining Elements in Canine Factor VIII. Molecular Therapy - Methods and Clinical Development, 2020, 17, 328-336.	4.1	2

#	Article	IF	Citations
37	Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study. Haemophilia, 2020, 26, 494-502.	2.1	44
38	Comprehensive Nâ€•and Oâ€glycosylation mapping of human coagulation factor V. Journal of Thrombosis and Haemostasis, 2020, 18, 1884-1892.	3.8	9
39	Updated Follow-up of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (SB-525) Gene Therapy in Adults with Severe Hemophilia a. Blood, 2020, 136, 12-12.	1.4	18
40	First-in-Human Phase 1/2 Clinical Trial of SIG-001, an Innovative Shielded Cell Therapy Platform, for Hemophilia Î². Blood, 2020, 136, 8-8.	1.4	4
41	Comparative glycosylation mapping of plasma-derived and recombinant human factor VIII. PLoS ONE, 2020, 15, e0233576.	2.5	13
42	Enhancing therapeutic efficacy of in vivo platelet-targeted gene therapy in hemophilia A mice. Blood Advances, 2020, 4, 5722-5734.	5.2	3
43	Healthcare Utilization and Health Related Quality of Life in Persons with Von Willebrand Disease. Blood, 2020, 136, 3-4.	1.4	2
44	Results of Genetic Analysis of 11,341 Participants Enrolled in the My Life, Our Future (MLOF) Hemophilia Genotyping Initiative. Blood, 2020, 136, 19-19.	1.4	2
45	Design of the Von Willebrand Factor in Pregnancy (VIP) Study. Blood, 2020, 136, 29-29.	1.4	2
46	A Multi-Omics Approach to X-Chromosome Inactivation (XCI) Identifies Severe Xci Skewing in Female Genetic Carriers of Hemophilia. Blood, 2020, 136, 19-20.	1.4	0
47	Hematology Utilization Group Studies Part VII (HUGS VII): Costs and Impact of Disease in Older Persons with Hemophilia. Blood, 2020, 136, 35-36.	1.4	0
48	The national blueprint for 21st century data and specimen collection and observational cohort studies: NHLBI State of the Science Workshop on factor VIII inhibitors. Haemophilia, 2019, 25, 590-594.	2.1	6
49	Whole Genome Sequencing Identifies CRISPLD2 as a Lung Function Gene in Children With Asthma. Chest, 2019, 156, 1068-1079.	0.8	5
50	Hemophilia trials in the twentyâ€first century: Defining patient important outcomes. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 184-192.	2.3	42
51	Cysteine Disulfides (Cys-ss-X) as Sensitive Plasma Biomarkers of Oxidative Stress. Scientific Reports, 2019, 9, 115.	3.3	35
52	von Willebrand Disease. , 2019, , 93-107.		0
53	Thrombotic Risk of Contraceptives and Other Hormonal Therapies. , 2019, , 637-650.		0
54	Updated Follow-up of the Alta Study, a Phase 1/2, Open Label, Adaptive, Dose-Ranging Study to Assess the Safety and Tolerability of SB-525 Gene Therapy in Adult Patients with Severe Hemophilia A. Blood, 2019, 134, 2060-2060.	1.4	14

#	Article	IF	Citations
55	Von Willebrand Disease Minimize Menorrhagia (VWDMin) Trial. Blood, 2019, 134, 1130-1130.	1.4	1
56	Clingen Coagulation Factor Deficiency Variant Curation Expert Panel: Meeting the Need for Recommendations to Curate Variants in the Coagulation Factor Genes. Blood, 2019, 134, 5794-5794.	1.4	1
57	Balance, falls, and exercise: Beliefs and experiences in people with hemophilia: A qualitative study. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 147-154.	2.3	14
58	Laboratory biomarkers for venous thromboembolism risk in patients with hematologic malignancies: A review. Thrombosis Research, 2018, 163, 138-145.	1.7	20
59	The frequency of joint hemorrhages and procedures in nonsevere hemophilia A vs B. Blood Advances, 2018, 2, 2136-2144.	5.2	69
60	Transfusion Medicine in Obstetrics. Transfusion Medicine Reviews, 2018, 32, 203-204.	2.0	0
61	A cross-sectional analysis of cardiovascular disease in the hemophilia population. Blood Advances, 2018, 2, 1325-1333.	5.2	43
62	Inhibitors in Hemophilias. , 2018, , 2023-2033.e5.		1
63	Inherited Bleeding Disorders in the Obstetric Patient. Transfusion Medicine Reviews, 2018, 32, 237-243.	2.0	21
64	Genotypes, phenotypes and whole genome sequence: Approaches from the My Life Our Future haemophilia project. Haemophilia, 2018, 24, 87-94.	2.1	32
65	Efficacy and Safety Results from a Phase 3b, Open-Label, Multicenter, Continuation Study of Rurioctocog Alfa Pegol for Prophylaxis in Previously Treated Patients with Severe Hemophilia A. Blood, 2018, 132, 2483-2483.	1.4	1
66	BIVV001: The First Investigational Factor VIII Therapy to Break Through the VWF Ceiling in Hemophilia A, with Potential for Extended Protection for One Week or Longer. Blood, 2018, 132, 636-636.	1.4	11
67	ASPIRE Final Results Confirm Established Safety and Sustained Efficacy for Up to 4 Years of Treatment With rFVIIIFc in Previously Treated Subjects With Severe Hemophilia A. Blood, 2018, 132, 1192-1192.	1.4	5
68	Chronic Kidney Disease (CKD) in the U.S. Hemophilia Population: A Cohort Study. Blood, 2018, 132, 2479-2479.	1.4	0
69	Effect of Intravenous and Oral N-Acetylcysteine Treatment in a Patient with Sickle Cell Disease at Disease Baseline. Blood, 2018, 132, 4911-4911.	1.4	0
70	Novel Structural Variants Originating in F8 Non-Coding Regions in Previously Unresolved Cases of Severe Hemophilia A. Blood, 2018, 132, 379-379.	1.4	1
71	von Willebrand factor proteolysis by ADAMTS-13 in patients on left ventricular assist device support. Journal of Heart and Lung Transplantation, 2017, 36, 477-479.	0.6	13
72	Management of hereditary antithrombin deficiency in pregnancy. Thrombosis Research, 2017, 157, 41-45.	1.7	23

#	Article	IF	Citations
73	Feasibility of the Von Willebrand disease PREVENT trial. Thrombosis Research, 2017, 156, 8-13.	1.7	9
74	von Willebrand disease Outreach into Integrated Care Education (VOICE): a call to action. Haemophilia, 2017, 23, e370-e373.	2.1	3
75	Efficacy and safety of full-length pegylated recombinant factor VIII with extended half-life in previously treated patients with hemophilia A: comparison of data between the general and Japanese study populations. International Journal of Hematology, 2017, 106, 704-710.	1.6	6
76	Clinical outcomes in a cohort of patients with heparinâ€induced thrombocytopenia. American Journal of Hematology, 2017, 92, 730-738.	4.1	49
77	Hepatitis C in haemophilia: time for treatment for all. Haemophilia, 2017, 23, 180-181.	2.1	6
78	Impacting inhibitor development in hemophilia A. Blood, 2017, 130, 1689-1690.	1.4	3
79	Novel approach to genetic analysis and results in 3000 hemophilia patients enrolled in the My Life, Our Future initiative. Blood Advances, 2017, 1, 824-834.	5.2	83
80	Preoperative management of factor XI deficiency with therapeutic plasma exchange: A case report and literature review. Journal of Clinical Apheresis, 2016, 31, 579-583.	1.3	8
81	Progress toward meeting the needs of adolescent females with bleeding disorders. Haemophilia, 2016, 22, 196-198.	2.1	5
82	Von Willebrand factor for menorrhagia: a survey and literature review. Haemophilia, 2016, 22, 397-402.	2.1	37
83	Low molecular weight heparin to prevent postpartum venous thromboembolism: A pilot study to assess the feasibility of a randomized, open-label trial. Thrombosis Research, 2016, 142, 17-20.	1.7	22
84	Defining von Willebrand disease. Blood, 2016, 127, 2373-2374.	1.4	3
85	Direct Oral Anticoagulants. Hematology/Oncology Clinics of North America, 2016, 30, 995-1006.	2.2	4
86	Recognizing the need for personalization of haemophilia patientâ€reported outcomes in the prophylaxis era. Haemophilia, 2016, 22, 825-832.	2.1	36
87	Genetic analysis of bleeding disorders. Haemophilia, 2016, 22, 79-83.	2.1	2
88	High-density lipoprotein modulates thrombosis by preventing von Willebrand factor self-association and subsequent platelet adhesion. Blood, 2016, 127, 637-645.	1.4	73
89	A prospective study of von Willebrand factor levels and bleeding in pregnant women with type 1 von Willebrand disease. Haemophilia, 2016, 22, e562-e564.	2.1	18
90	Longâ€term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A. Haemophilia, 2016, 22, 72-80.	2.1	98

#	Article	IF	Citations
91	Aging among persons with hemophilia: contemporary concerns. Seminars in Hematology, 2016, 53, 35-39.	3.4	31
92	A Pilot Study of High-Dose N-Acetylcysteine Infusion in Patients with Sickle Cell Disease. Blood, 2016, 128, 1299-1299.	1.4	4
93	Von Willebrand Factor to Prevent Postpartum Hemorrhage. Blood, 2016, 128, 1400-1400.	1.4	1
94	Novel Approach to and Results of Genetic Analysis of 3000 Hemophilia Patients Enrolled in the MyLifeOurFuture Initiative. Blood, 2016, 128, 205-205.	1.4	1
95	Modelling FVIII Levels for Prediction of Zero Spontaneous-Joint Bleeding in a Cohort of Severe Hemophilia a Subjects with Target Joints Initiated on Tertiary Prophylaxis. Blood, 2016, 128, 2576-2576.	1.4	3
96	Potential Mechanisms for Enhanced Activity of Von Willebrand Factor in Patients with Sickle Cell Disease. Blood, 2016, 128, 3716-3716.	1.4	4
97	Falls and associated complications in adults with haemophilia. The Journal of Haemophilia Practice, 2016, 3, 37-42.	0.4	3
98	Thrombotic Disorders. , 2016, , 439-446.		0
99	Prophylaxis in Patients with Hemophilia a and Its Impact on Quality of Life Using the Specific Index Haem-a-Qol at a Hospital in Paraguay. Blood, 2016, 128, 4959-4959.	1.4	0
100	Longitudinal Analysis of Long-Term Safety and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIFc) in Adults/Adolescents with Severe Hemophilia a. Blood, 2016, 128, 1413-1413.	1.4	0
101	A Quantitative Assay of In Vivo Cleavage of Von Willebrand Factor By ADAMTS13 Reveals Excessive Cleavage in Type 2B Von Willebrand Disease and Diminished Cleavage in Thrombotic Thrombocytopenic Purpura. Blood, 2016, 128, 2532-2532.	1.4	0
102	Characteristics Associated With Annual Bleeding Frequency Among Hemophilia Patients In The United States. Value in Health, 2015, 18, A682.	0.3	0
103	Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. Blood, 2015, 126, 1078-1085.	1.4	224
104	Diagnosis and management of thrombosis in pregnancy. Birth Defects Research Part C: Embryo Today Reviews, 2015, 105, 185-189.	3.6	19
105	Low-molecular-weight heparin to prevent postpartum venous thromboembolism. Thrombosis and Haemostasis, 2015, 113, 212-216.	3.4	25
106	Prevention of bleeding in hemophilia patients with high-titer inhibitors. Expert Review of Hematology, 2015, 8, 375-382.	2.2	3
107	Postpartum von Willebrand factor levels in women with and without von Willebrand disease and implications for prophylaxis. Haemophilia, 2015, 21, 81-87.	2.1	98
108	Brain-derived microparticles induce systemic coagulation in a murine model of traumatic brain injury. Blood, 2015, 125, 2151-2159.	1.4	127

#	Article	IF	Citations
109	Antithrombin Concentrates Use in Children on Extracorporeal Membrane Oxygenation. Pediatric Critical Care Medicine, 2015, 16, 264-269.	0.5	26
110	Evaluation of Cell Types and Morphologies in Sickle Cell Disease with an Imaging Flow Cytometer. Blood, 2015, 126, 972-972.	1.4	9
111	An Integrated Analysis of Long Term Safety of an Extended Half-Life, Pegylated, Full-Length Recombinant Factor VIII (BAX 855) in the Treatment of Hemophilia a. Blood, 2015, 126, 3522-3522.	1.4	0
112	Rituximab for treatment of inhibitors in haemophilia A. Thrombosis and Haemostasis, 2014, 112, 445-458.	3.4	43
113	Atherosclerosis is not a risk factor for antiplatelet factor 4/heparin antibody formation after cardiopulmonary bypass surgery. Thrombosis and Haemostasis, 2014, 111, 1191-1193.	3.4	1
114	Monitoring target-specific oral anticoagulants. Hematology American Society of Hematology Education Program, 2014, 2014, 329-333.	2.5	3
115	What is the effect of rivaroxaban on routine coagulation tests?. Hematology American Society of Hematology Education Program, 2014, 2014, 334-336.	2.5	7
116	von Willebrand Factor and Aging. Seminars in Thrombosis and Hemostasis, 2014, 40, 640-644.	2.7	22
117	The Therapeutic Use of Plasma Components and Derivatives. , 2014, , 3171-3181.		0
118	Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories. Haemophilia, 2014, 20, 294-300.	2.1	84
119	<scp>N</scp>â€Acetylcysteine: an old drug, a new insight, a potentially effective treatment for thrombotic thrombocytopenic purpura. Transfusion, 2014, 54, 1205-1207.	1.6	11
120	Prophylaxis in real life scenarios. Haemophilia, 2014, 20, 106-113.	2.1	22
121	A Cross-Sectional Analysis of Cardiovascular Disease in the Hemophilia Population. Blood, 2014, 124, 2836-2836.	1.4	4
122	Complex Changes in von Willebrand Factor-Associated Parameters Are Acquired during Uncomplicated Pregnancy. PLoS ONE, 2014, 9, e112935.	2.5	47
123	Quantitative Analysis of Small Molecular Weight Thiols and Disulfides in Blood from a Sickle Cell Disease Patient Infused with N-Acetyl-L-Cysteine. Blood, 2014, 124, 2662-2662.	1.4	0
124	Brain-Derived Microparticles Induce Systemic Coagulation Associated with Traumatic Brain Injury. Blood, 2014, 124, 1497-1497.	1.4	0
125	Monitoring target specific anticoagulants. Journal of Thrombosis and Thrombolysis, 2013, 35, 387-390.	2.1	8
126	Case studies in the management of refractory bleeding in patients with haemophilia A and inhibitors. Haemophilia, 2013, 19, e151-66.	2.1	6

#	Article	IF	Citations
127	Normal cleavage of von Willebrand factor by ADAMTS-13 in the absence of factorÂVIII in patients with severe hemophiliaÂA. Journal of Thrombosis and Haemostasis, 2013, 11, 1769-1772.	3.8	7
128	von Willebrand Disease. , 2013, , 90-102.		3
129	Similarity in joint function limitation in Type 3 von Willebrand's disease and moderate haemophilia A. Haemophilia, 2013, 19, 595-601.	2.1	12
130	Factor VIII mutation and desmopressinâ€responsiveness in 62 patients with mild haemophilia A. Haemophilia, 2013, 19, 720-726.	2.1	21
131	Novel diagnostic assays for heparin-induced thrombocytopenia. Blood, 2013, 121, 3727-3732.	1.4	41
132	Superficial venous thrombosis: cause for concern. Blood, 2013, 122, 1691-1692.	1.4	1
133	Prevention and treatment of venous thromboembolism in pregnancy in patients with hereditary antithrombin deficiency. International Journal of Women's Health, 2013, 5, 233.	2.6	38
134	Thrombotic Risk of Contraceptives and Other Hormonal Therapies. , 2013, , 603-615.		0
135	Recombinant Factor VIII Combined With Recombinant Von Willebrand Factor In Patients With Severe Hemophilia A: A Prospective Clinical Study Of Safety and Pharmacokinetics. Blood, 2013, 122, 336-336.	1.4	0
136	An algorithmic approach to peripheral artery disease in hemophilia. Blood Coagulation and Fibrinolysis, 2012, 23, 23-29.	1.0	4
137	The aging patient with hemophilia. American Journal of Hematology, 2012, 87, S27-32.	4.1	23
138	Pharmacokinetics and safety of OBIâ€1, a recombinant B domainâ€deleted porcine factor VIII, in subjects with haemophilia A. Haemophilia, 2012, 18, 798-804.	2.1	61
139	Novel Diagnostic Assays for Heparin-Induced Thrombocytopenia. Blood, 2012, 120, 267-267.	1.4	1
140	Clinical challenges within the aging hemophilia population. Thrombosis Research, 2011, 127, S10-S13.	1.7	24
141	False normal von Willebrand factor activity by monoclonal antibody-based ELISA in a patient with type 2A(IID) von Willebrand disease. Thrombosis and Haemostasis, 2011, 106, 1224-1225.	3.4	4
142	The longitudinal effect of body adiposity on joint mobility in young males with Haemophilia A. Haemophilia, 2011, 17, 196-203.	2.1	47
143	When should prophylaxis therapy in inhibitor patients be considered?. Haemophilia, 2011, 17, e849-57.	2.1	26
144	Role of exercise and physical activity on haemophilic arthropathy, fall prevention and osteoporosis. Haemophilia, 2011, 17, e870-6.	2.1	46

#	Article	IF	Citations
145	Surveillance of female patients with inherited bleeding disorders in United States Haemophilia Treatment Centres. Haemophilia, 2011, 17, 6-13.	2.1	71
146	Acquired Disorders of Platelet Function. Hematology American Society of Hematology Education Program, 2011, 2011, 391-396.	2.5	84
147	Intake of Omega-3 Fatty Acids Suppresses Shear-Induced Platelet Aggregation and Reduces Lipid Raft Localization of the Platelet Glycoprotein Ib-IX-V Complex. Blood, 2011, 118, 1128-1128.	1.4	1
148	Phase II Trial of Rituximab in the Treatment of Inhibitors in Congenital Hemophilia A: Results of the RICH Study. Blood, 2011, 118, 27-27.	1.4	2
149	Treatment of Pregnant Female with Mesenteric Vein Thrombosis and History of Spontaneous Fetal Losses. , 2011, 8, .		0
150	Factor VIII Mutation and Desmopressin-Responsiveness in 63 Patients with Mild Hemophilia A. Blood, 2011, 118, 1203-1203.	1.4	0
151	Pregnancy-Induced Shifts in Von Willebrand Factor (VWF) Parameters Support a Prolongation in VWF Survival. Blood, 2011, 118, 33-33.	1.4	0
152	How we treat: Haematuria in adults with haemophilia. Haemophilia, 2010, 16, 683-685.	2.1	16
153	Mean platelet volume as a predictor of cardiovascular risk: a systematic review and metaâ€analysis. Journal of Thrombosis and Haemostasis, 2010, 8, 148-156.	3.8	813
154	The HIT Expert Probability (HEP) Score: a novel preâ€test probability model for heparinâ€induced thrombocytopenia based on broad expert opinion. Journal of Thrombosis and Haemostasis, 2010, 8, 2642-2650.	3.8	229
155	Dose of Prophylactic Platelet Transfusions and Prevention of Hemorrhage. New England Journal of Medicine, 2010, 362, 600-613.	27.0	563
156	A single-center experience of preemptive anticoagulation for patients with risk factors for allograft thrombosis in renal transplantation. Clinical Nephrology, 2010, 74, 351-357.	0.7	22
157	Normal Cleavage of Von Willebrand Factor by ADAMTS13 In the Absence of Factor VIII In Patients with Severe Hemophilia A. Blood, 2010, 116, 2114-2114.	1.4	0
158	Platelet and monocyte antigenic complexes in the pathogenesis of heparin-induced thrombocytopenia (HIT). Journal of Thrombosis and Haemostasis, 2009, 7, 249-252.	3.8	21
159	Von Willebrand disease and other bleeding disorders in women: consensus on diagnosis and management from an international expert panel. American Journal of Obstetrics and Gynecology, 2009, 201, 12.e1-12.e8.	1.3	130
160	Platelet von Willebrand factor determination does not improve the diagnosis of patients with suspected Type 1 von Willebrand disease. Haemophilia, 2009, 15, 131-134.	2.1	0
161	Bleeding symptoms and laboratory correlation in patients with severe von Willebrand disease. Haemophilia, 2009, 15, 918-925.	2.1	30
162	Emerging clinical concerns in the ageing haemophilia patient. Haemophilia, 2009, 15, 1197-1209.	2.1	61

#	Article	IF	Citations
163	Interlaboratory agreement in the monitoring of unfractionated heparin using the anti-factorÂXa-correlated activated partial thromboplastin time. Journal of Thrombosis and Haemostasis, 2009, 7, 80-86.	3.8	58
164	Secondary prophylaxis with recombinant activated factor VII improves healthâ€rrelated quality of life of haemophilia patients with inhibitors. Haemophilia, 2008, 14, 466-475.	2.1	85
165	Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis. New England Journal of Medicine, 2008, 358, 2240-2248.	27.0	1,941
166	Evaluation of thromboelastography for monitoring recombinant activated factor VII ex vivo in haemophilia A and B patients with inhibitors: a multicentre trial. Blood Coagulation and Fibrinolysis, 2008, 19, 276-282.	1.0	53
167	Treatment of Acute Bleeds in Acquired Hemophilia: Analysis from the Hemophilia Research Society (HRS) and Hemophilia and Thrombosis Research Society (HTRS) Registry.. Blood, 2008, 112, 2285-2285.	1.4	0
168	Similarity in Joint Function Limitation in Type 3 VWD and Moderate Hemophilia A. Blood, 2008, 112, 426-426.	1.4	5
169	Chronic hepatitis B and other correlates of spontaneous clearance of hepatitis C virus among HIV-infected people with hemophilia. Aids, 2007, 21, 1631-1636.	2.2	12
170	5B.3 Counseling of women with thrombophilia. Thrombosis Research, 2007, 119, S67-S68.	1.7	0
171	Preanalytical conditions that affect coagulation testing, including hormonal status and therapy. Journal of Thrombosis and Haemostasis, 2007, 5, 855-858.	3.8	49
172	von Willebrand disease: treatment with or without factor VIII?. Journal of Thrombosis and Haemostasis, 2007, 5, 1113-1114.	3.8	2
173	Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. Journal of Thrombosis and Haemostasis, 2007, 5, 1904-1913.	3.8	320
174	Uncertain times for research on hemophilia and allied disorders. Journal of Thrombosis and Haemostasis, 2006, 4, 681-681.	3.8	1
175	Congenital factor VII deficiency: therapy with recombinant activated factor VII - a critical appraisal. Haemophilia, 2006, 12, 19-27.	2.1	97
176	Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nature Medicine, 2006, 12, 342-347.	30.7	1,865
177	An unusual case of toe ulceration. Vascular Medicine, 2006, 11, 35-37.	1.5	2
178	Randomized, Prospective Clinical Trial of rFVIIa for Secondary Prophylaxis in Hemophilia Patients with Inhibitors.. Blood, 2006, 108, 766-766.	1.4	10
179	Secondary Prophylaxis with rFVIIa Improves Quality of Life of Hemophilia Patients with Inhibitors and Frequent Bleeds.. Blood, 2006, 108, 1028-1028.	1.4	1
180	Acquired Hemophilia: Analysis of the Experience of a Regional Hemophilia Center.. Blood, 2006, 108, 4055-4055.	1.4	0

#	Article	IF	Citations
181	Correlates of spontaneous clearance of hepatitis C virus among people with hemophilia. Blood, 2005, 107, 892-897.	1.4	74
182	Fresh frozen plasma prepared with amotosalen HCl (Sâ€59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies. Transfusion, 2005, 45, 1362-1372.	1.6	65
183	Defining effective therapies in transfusion medicine and hemostasis: new opportunities with the TMH Network. Transfusion, 2005, 45, 1404-1406.	1.6	17
184	Phase I study of the novel taxane CT-2103 in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2005, 55, 497-501.	2.3	30
185	Percutaneous Interventions in the Coagulopathic Patient. Seminars in Interventional Radiology, 2005, 22, 88-94.	0.8	10
186	Total Knee Arthroplasty Using Recombinant Factor VII in Hemophilia-A Patients with Inhibitors: A Report of Three Cases. Journal of Bone and Joint Surgery - Series A, 2004, 86, 2519-2521.	3.0	10
187	Von Willebrand Factor Levels Do Not Increase with Age in Patients with Type 1 Von Willebrand Disease.. Blood, 2004, 104, 4028-4028.	1.4	0
188	Role of splenectomy in patients with refractory or relapsed thrombotic thrombocytopenic purpura. Journal of Clinical Apheresis, 2003, 18, 51-54.	1.3	43
189	Use of recombinant human antithrombin in patients with congenital antithrombin deficiency undergoing surgical procedures. Transfusion, 2003, 43, 390-394.	1.6	54
190	Thrombotic Disorders: Diagnosis and Treatment. Hematology American Society of Hematology Education Program, 2003, 2003, 520-539.	2.5	53
191	Approaches to successful total knee arthroplasty in haemophilia A patients with inhibitors. Haemophilia, 2002, 8, 706-710.	2.1	18
192	Characterization of High-Risk HIV-1 Seronegative Hemophiliacs. Clinical Immunology, 2001, 98, 200-211.	3.2	56
193	Heparin-induced thrombocytopenia: bovine versus porcine heparin in cardiopulmonary bypass surgery. Annals of Thoracic Surgery, 2001, 71, 1920-1924.	1.3	34
194	Genetic Predisposition to Bleeding during Oral Anticoagulant Therapy: Evidence for Common Founder Mutations (FIXVal-10 and FIXThr-10) and an Independent CpG Hotspot Mutation (FIXThr-10). Thrombosis and Haemostasis, 2001, 85, 454-457.	3.4	25
195	Thrombophilia: What's a Practitioner to Do?. Hematology American Society of Hematology Education Program, 2001, 2001, 322-338.	2.5	10
196	Thrombophilia: What's a Practitioner to Do?. Hematology American Society of Hematology Education Program, 2001, 2001, 322-338.	2.5	0
197	Nonsense mutation in exon V of the factor XI gene does not abolish platelet factor XI expression. British Journal of Haematology, 2000, 111, 91-95.	2.5	0
198	Thrombotic Thrombocytopenic Purpura: A Paradigm Shift?. Thrombosis and Haemostasis, 2000, 84, 528-535.	3.4	30

#	Article	IF	Citations
199	Nonsense mutation in exon V of the factor XI gene does not abolish platelet factor XI expression. British Journal of Haematology, 2000, 111, 91-95.	2.5	11
200	Arterial shear stress stimulates surface expression of the endothelial glycoprotein Ib complex. , 1999, 73, 508-521.		7
201	Phenotypic Expressions of CCR5-Î”32/Î”32 Homozygosity. Journal of Acquired Immune Deficiency Syndromes, 1999, 22, 75.	0.3	41
202	Activated Protein C Resistance, Factor V Leiden, and Central Retinal Vein Occlusion in Young Adults. JAMA Ophthalmology, 1998, 116, 577.	2.4	83
203	To GpIb or not to GpIb. Blood, 1998, 92, 339-340.	1.4	1
204	Tissue-Specific Expression of Functional Platelet Factor XI Is Independent of Plasma Factor XI Expression. Blood, 1998, 91, 3800-3807.	1.4	26
205	Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Journal of Cardiothoracic and Vascular Anesthesia, 1997, 11, 804.	1.3	0
206	Human Endothelial Cells in Culture and In Vivo Express on Their Surface All Four Components of the Glycoprotein Ib/IX/V Complex. Blood, 1997, 90, 2660-2669.	1.4	58
207	The Bernard-Soulier Syndrome. Trends in Cardiovascular Medicine, 1997, 7, 239-244.	4.9	1
208	Parvovirus B19 quiescence during the course of human immunodeficiency virus infection in persons with hemophilia. , 1997, 56, 248-251.		7
209	Parvovirus B19 quiescence during the course of human immunodeficiency virus infection in persons with hemophilia. American Journal of Hematology, 1997, 56, 248-251.	4.1	1
210	Microvascular disease in diabetes mellitus. European Journal of Cardiovascular Prevention and Rehabilitation, 1997, 4, 70-75.	1.5	7
211	Prevalence of Heparin-Associated Antibodies Without Thrombosis in Patients Undergoing Cardiopulmonary Bypass Surgery. Circulation, 1997, 95, 1242-1246.	1.6	293
212	Human Endothelial Cells in Culture and In Vivo Express on Their Surface All Four Components of the Glycoprotein Ib/IX/V Complex. Blood, 1997, 90, 2660-2669.	1.4	5
213	Microvascular disease in diabetes mellitus. Coronary Artery Disease, 1996, 7, 702-707.	0.7	1
214	Identification of a Mutation in a GATA Binding Site of the Platelet Glycoprotein IbÎ² Promoter Resulting in the Bernard-Soulier Syndrome. Journal of Biological Chemistry, 1996, 271, 22076-22080.	3.4	134
215	Laboratory evaluation of von Willebrand disease. Clinical Chemistry, 1995, 41, 489-490.	3.2	3
216	Identification of a patient with Bernard-Soulier syndrome and a deletion in the DiGeorge/Velo-cardio-facial chromosomal region in 22q11.2. Human Molecular Genetics, 1995, 4, 763-766.	2.9	144

#	Article	IF	Citations
217	A plasmid mediating production of a beta-lactamase by Stenotrophomonas maltophilia. Current Therapeutic Research, 1995, 56, 152-162.	1.2	5
218	Plasminogen Activator Inhibitorâ€1 Expression by Brain Microvessel Endothelial Cells Is Inhibited by Elevated Glucose. Journal of Neurochemistry, 1994, 63, 903-909.	3.9	17
219	Complementary DNA cloning of the alternatively expressed endothelial cell glycoprotein Ib beta (GPIb) Tj ETQq1 1 0.784314 rgBT /Ov 93, 2417-2424.	8.2	43
220	Plasminogen activator inhibitor-1 mRNA is expressed in platelets and megakaryocytes and the megakaryoblastic cell line CHRF-288.. Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1993, 13, 669-674.	3.9	48
221	Tumor necrosis factor-alpha modulation of glycoprotein Ib alpha expression in human endothelial and erythroleukemia cells. Blood, 1992, 80, 153-161.	1.4	12
222	Molecular basis of human von Willebrand disease: analysis of platelet von Willebrand factor mRNA.. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 3723-3727.	7.1	126
223	The addition of endothelial cell growth factor and heparin to human umbilical vein endothelial cell cultures decreases plasminogen activator inhibitor-1 expression.. Journal of Clinical Investigation, 1988, 82, 579-585.	8.2	82
224	RsaI RFLP in the human von Willebrand factor gene. Nucleic Acids Research, 1987, 15, 5909-5909.	14.5	12
225	SacI RFLP in the human von Willebrand factor gene. Nucleic Acids Research, 1987, 15, 6766-6766.	14.5	21
226	Miscellaneous Questions. , 0, , 206-206.		0